胃癌组织中VEGF、HER-2/neu的研究  

Study of VEGF and HER-2/neu in gastric cancer

作　　者：陈锦章[1] 陈斌[1] 郑航[1] 黄宇贤[1] 罗荣城[1] 

机构地区：[1]南方医科大学南方医院,广东广州510515

出　　处：《山东医药》2008年第32期13-15,共3页Shandong Medical Journal

基　　金：广东省自然科学基金资助项目(2004037050)

摘　　要：目的研究血管内皮生长因子(VEGF)和表皮生长因子受体2(HER-2/neu)在胃腺癌组织中的表达及其与胃癌各临床病理特征、胃癌患者生存期之间的关系。方法通过回顾性研究,随访到有103例完整生存期的胃癌患者,应用免疫组化方法检测他们标本中VEGF、HER-2/neu的表达,并应用统计学方法分析检测结果与临床病理特征、生存期之间的关系。结果胃癌组织中VEGF、HER-2/neu的阳性表达率分别为46.6%、31.1%,胃正常组织中二者均无表达;VEGF、HER-2/neu表达与肿瘤的浸润深度、病理分期、淋巴结转移、远处转移相关(P<0.05);VEGF与HER-2/neu阳性表达与生存期相关。结论检测胃癌组织中VEGF、HER-2/neu表达有助于临床判断患者预后。Objective To investigate the expression of vascular endothehal growth factor （VEGF） and epidermal growth factor receptor 2 （HER-2） in gastric cancer and their relationship with clinical pathologic character and with survival. Methods The expression of VEGF and HER-2/neu in gastric cancer were studied by immunohistochemical technique. Their detect outcome and clinical pathologic character were analyzed. Results In gastric cancer specimens, the positive rate of VEGF and HER-2/nen was 46.6% and 31.1% respectively. The expression of VEGF and HER-2/neu were not found in gastric normal tissue. The positive expression rate of VEGF and HER-2/neu were related to depth of invasion, clinical stage, lymph node and distant metastasis of gastric cancer patients （ P 〈 0.05 ）. VEGF and HER-2/neu expression was related to survival time. Conclusion The expression of VEGF and HER-2/neu in gastric cancer tissues can shed light on the judgement of the prognosis.

关 键 词：胃肿瘤 血管内皮生长因子 受体 表皮生长因子 靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]